Consensus Alvotech

Stocks

ALVO

LU2458332611

Biotechnology & Medical Research

End-of-day quote Nasdaq 19/10/2026			5-day change	1st Jan Change
5.030 ^USD	+0.60%		-6.51%	-1.95%

10:23am	Nordic stocks in North America - Ericsson up 0.7 percent	FW
20/10	Alvotech's Manufacturing Progress, Simponi Launch Potential Support Recovery, UBS Says	MT

Evolution of the Average Target: Alvotech

Evolution of the Target Price: Alvotech

Changes in Analyst Recommendations: Alvotech

da1b2cfa.hxEFtSxgFtEzbWPKbsQiQrjOKZ_AaunOYVIhe-U3OGk.y0dOhBs3RIdQHlSOL4trN8n7aP2GX9j8DCBET5RuC1nyVDLyYDRfkwAjLg~a33bf67da57d0ada53a3228f91aa68e8

Analysts' recommendations: Alvotech

20/10	Alvotech's Manufacturing Progress, Simponi Launch Potential Support Recovery, UBS Says	MT
16/09	Alvotech Shares Rise After Double Upgrade From Barclays	MT
16/09	Barclays Upgrades Alvotech to Overweight From Underweight, Adjusts PT to $8 From $4	MT
24/08	Alvotech's Q4 Approval, Launch Timelines Remain Intact, UBS Says	MT
24/08	BofA Securities Initiates Alvotech at Buy With $7 Price Target	MT
24/03	UBS Adjusts Alvotech Price Target to $6 From $10, Maintains Buy Rating	MT
24/03	Deutsche Bank Adjusts Alvotech Price Target to $4 From $8, Maintains Hold Rating	MT
22/12	Stockholm Bullets - Viscaria Soars on Buy Recommendation	FW
18/11	UBS Adjusts Alvotech Price Target to $10 From $13, Maintains Buy Rating	MT
05/11	Alvotech Shares Fall After Deutsche Bank Downgrade	MT
04/11	Deutsche Bank Downgrades Alvotech to Hold From Buy, Adjusts Price Target to $8 From $14	MT
04/11	Deutsche Bank Downgrades Alvotech to Hold From Buy, Cuts Price Target to $8 From $14	MT
03/11	Alvotech Shares Slide on FDA Demands for Application for Arthritis Drug Biosimilar	DJ
03/11	Top Premarket Decliners	MT
03/11	Alvotech's Potential Arthritis Biosimilar Receives FDA Complete Response Letter; Shares Down Pre-Bell	MT
03/11	Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05	CI
15/25/15	Alvotech Shares Rise After Morgan Stanley Upgrade	MT
14/25/14	Morgan Stanley Upgrades Alvotech to Overweight From Equalweight, Price Target is $14	MT
23/25/23	Alvotech Set to Benefit from Opportunities in Biosimilars Market, Deutsche Bank Says	MT
23/25/23	Deutsche Bank Upgrades Alvotech to Buy From Hold, Price Target is $14	MT
21/25/21	UBS Says Alvotech Set for H2 Growth on Pipeline Launches, Private Label Deal	MT
18/25/18	UBS Adjusts Price Target on Alvotech to $14 From $16, Maintains Buy Rating	MT
25/24/25	Barclays Adjusts Price Target on Alvotech to $18 From $22, Maintains Overweight Rating	MT
24/24/24	Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating	MT
22/24/22	Barclays Raises Price Target on Alvotech to $20 From $17, Maintains Overweight Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALVOTECH					+40.62%
	WUXI APPTEC CO., LTD.					+29.95%
	LONZA GROUP AG					+11.46%
	ARGENX SE					+29.38%
	IQVIA HOLDINGS INC.					+12.36%
	BEONE MEDICINES AG					+13.51%
	REVOLUTION MEDICINES, INC.					+31.18%
	CELLTRION, INC.					+35.68%
	WUXI BIOLOGICS (CAYMAN) INC.					+20.18%
	GENMAB A/S					+6.68%
	Average					+23.10%
	Weighted average by Cap.					+22.15%